Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2004;35:e159-e162
Published online before print April 22, 2004, doi: 10.1161/01.STR.0000127420.10990.76
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
35/6/e159    most recent
01.STR.0000127420.10990.76v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adair, J. C.
Right arrow Articles by Rosenberg, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adair, J. C.
Right arrow Articles by Rosenberg, G. A.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Alzheimer's Disease
Related Collections
Right arrow Behavioral/psychosocial - stroke
Right arrow Other Stroke

(Stroke. 2004;35:e159.)
© 2004 American Heart Association, Inc.


Research Reports

Measurement of Gelatinase B (MMP-9) in the Cerebrospinal Fluid of Patients With Vascular Dementia and Alzheimer Disease

John C. Adair, MD; Julius Charlie, MD; John E. Dencoff, BS; Jeffrey A. Kaye, MD; Joseph F. Quinn, MD; Richard M. Camicioli, MD; William G. Stetler-Stevenson, MD, PhD Gary A. Rosenberg, MD

From the Departments of Neurology (J.C.A., J.E.D., J.C., G.A.R.), Cell Biology and Physiology (G.A.R.), and Neuroscience (G.A.R.), the University of New Mexico School of Medicine, Albuquerque, NM; Veterans Administration Health Center (J.C.A.), Albuquerque, NM; the Department of Neurology (J.A.K., J.F.Q.), Oregon Health Science University, Portland, Ore; the Department of Medicine (R.M.C.), University of Alberta, Edmonton, AB, Canada; Extracellular Matrix Pathology Section (W.G.S.-S.), Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Md.

Correspondence to Dr John C. Adair, Department of Neurology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131. E-mail adair.john{at}albuquerque.va.gov

Background and Purpose— Vascular causes of dementia are increasing in importance because of the aging of the population. Biological markers to distinguish patients with vascular dementia (VaD) from Alzheimer disease (AD) would be very useful. Because cerebrovascular disease increases expression of brain matrix metalloproteinases (MMPs) and tissue inhibitors to metalloproteinases (TIMPs), we hypothesized that MMPs would be elevated in the cerebrospinal fluid (CSF) of patients with VaD, but not in patients with AD.

Methods— Fifteen patients with VaD were identified, including dementia caused by multiple infarcts and progressive dementia caused by disease of the small cerebral blood vessels. Patients were followed-up for 4 to 10 years to confirm the diagnosis. Thirty patients with AD were also studied. Patients had CSF collected at their initial evaluation. Gelatinase A (MMP-2) and gelatinase B (MMP-9) were quantified by gelatin-substrate zymography, and TIMPs were measured by reverse zymography. Control CSF was obtained from neurologically normal subjects.

Results— MMP-9 levels were significantly elevated in the CSF of VaD patients compared either to those with AD (P<0.0001) or to controls. MMP-2, TIMP-1, and TIMP-2 were similar in patient groups and controls.

Conclusions— Patients with multiinfarct and small vessel VaD have elevated levels of MMP-9 in the CSF compared with AD and controls. Although CSF MMP-9 increases in other neurological conditions and is not specific for VaD, it could provide an additional biological marker for the separation of patients with VaD and AD.


Key Words: matrix metalloproteinase • dementia




This article has been cited by other articles:


Home page
StrokeHome page
E. H. Lo and G. A. Rosenberg
The Neurovascular Unit in Health and Disease: Introduction
Stroke, March 1, 2009; 40(3_suppl_1): S2 - S3.
[Full Text] [PDF]


Home page
StrokeHome page
G. A. Rosenberg
Inflammation and White Matter Damage in Vascular Cognitive Impairment
Stroke, March 1, 2009; 40(3_suppl_1): S20 - S23.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. Tian, S. A. Greenberg, S. W. Kong, J. Altschuler, I. S. Kohane, and P. J. Park
Discovering statistically significant pathways in expression profiling studies
PNAS, September 20, 2005; 102(38): 13544 - 13549.
[Abstract] [Full Text] [PDF]